1. Home
  2. DPRO vs NKTX Comparison

DPRO vs NKTX Comparison

Compare DPRO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

N/A

Current Price

$3.00

Market Cap

208.8M

Sector

Industrials

ML Signal

N/A

Logo Nkarta Inc.

NKTX

Nkarta Inc.

N/A

Current Price

$1.49

Market Cap

198.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DPRO
NKTX
Founded
1998
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.8M
198.2M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
DPRO
NKTX
Price
$3.00
$1.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
★ $10.66
$10.50
AVG Volume (30 Days)
703.9K
★ 1.6M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 11.88
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$101.27
N/A
Revenue Next Year
$135.54
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.68
$1.13
52 Week High
$10.62
$3.72

Technical Indicators

Market Signals
Indicator
DPRO
NKTX
Relative Strength Index (RSI) 34.65 37.50
Support Level N/A N/A
Resistance Level $5.77 $1.88
Average True Range (ATR) 0.27 0.18
MACD 0.02 0.01
Stochastic Oscillator 29.17 48.08

Price Performance

Historical Comparison
DPRO
NKTX

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: